Genomic Testing Cooperative

Through DNA and RNA sequencing we identified a new CAR T-cell construct that caused CD4+ CAR T-Cell lymphoma in a patient previously treated with Cilta-cel CAR T-Cell Therapy for multiple myeloma. This is a unique capability of GTC’s testing.    GTC’s NEJM publication resulting from collaborative efforts with our partners: Dana-Farber Cancer Institute/Harvard Medical School, Georgetown University, Brigham and Women’s Hospital, and the National Institute of Medicine.    Learn more: https://lnkd.in/dzQZPXKF This publication highlights our commitment to advancing genomics and precision medicine through strong collaborations and innovative research. #Lymphoma #NEJM #RNA

In honor of Sarcoma Awareness Month GTC would like to highlight the importance of RNA testing since gene fusions are one of dominate abnormalities in these tumors like the EWSR1. Learn more about RNA testing: https://lnkd.in/d8NzX7b #Sarcomaawarenessmonth #Ewingsarcoma #Sarcoma

A comprehensive molecular evaluation will help you identify both common and rare abnormalities you may not routinely test for in traditional pathology workups. Running one comprehensive test may also be more cost-effective than traditional approaches. Learn more: https://lnkd.in/gBmGD6u #RNA #NGS #CGP

Quantify your detected mutations with Liquid Trace GTC's Liquid Trace reports now include a graphic presentation of the detected mutations as quantified per 1 mL of plasma or CSF. Learn more: https://lnkd.in/duiFUP8F #CSF #Liquidbiopsy #cfRNA

GTC is hiring for several positions including Molecular CLS, hematopathologist, Molecular QA Manager, and more. Check out our careers page for more info: https://lnkd.in/d7dyafk #CLS #Pathology #Hiring

Tarlatamab has recently been approved for patients with small cell lung cancer (SCLC) who express Delta-like ligand (DLL3). GTC's Liquid Trace Solid Tumor and Solid Tumor Profile Plus can help identify patients who would be candidates for this therapeutic.  Learn more: https://lnkd.in/gBmGD6u #Amgen #Tarlatamab #RNA #cfRNA #Geneexpression #DLL3

A Better way to internalize next-gen sequencing ✓ Comprehensive evaluation of DNA and RNA with AI software's all developed in house in the USA ✓ All work done by licensed technologies and board-certified pathologists ✓ Innovation pipeline keeps testing current ✓ Covered by Medicare Learn more: https://lnkd.in/g4EeP-j #RNA #cfRNA #NGS

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology.  GTC will become an early technology access member of BioAI's global ecosystem of clinical laboratories.   Read the full PR https://lnkd.in/drez2sNM #Digitalpathology #AI #NGS BioAI

GTC's cfRNA can be used to immune profile patients with cancer for myeloid and lymphoid deficiencies and more. Check out our poster from ASCO: https://lnkd.in/dNa8MbyP #Myeloidbiomarkers #Immuneprofiling #immunephenotyping